Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms

Summary

Dickkopf-3 (Dkk3) has been proposed as tumour suppressor gene and a marker for tumour blood vessels. We analysed the expression and function of Dkk3 in platelets and megakaryocytes from healthy controls and patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN). Dkk3 protein and gene expression in platelets was compared with endothelial and other blood cell populations by ELISA, real-time PCR, and immunofluorescence. Moreover, megakaryocytes were isolated from bone marrow aspirates by CD61 microbeads. Immunohisto-chemical studies of Dkk3 expression were performed in essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF) and control reactive bone marrow cases (each n=10). Compared to all other blood cell populations platelets showed the highest concentration of Dkk3 protein (150 ± 19 ng/mg total protein). A strong DKK3 gene and protein expression was also observed in isolated megakaryocytes. Dkk3 co-localised with VEGF in α-granules of platelets and was released similar to VEGF upon stimulation. Addition of recombinant Dkk3 had no influence on blood coagulation (aPTT, INR) and platelet aggregation. Significantly more Dkk3⁺ megakaryocytes/mm² could be found in bone marrow biopsies from patients with MPN (ET 40 ± 10, PV 31 ± 4, PMF 22 ± 3) than in controls (15 ± 3). The mean proportion of Dkk3⁺ megakaryocytes was increased in MPN as well (ET 83% ± 15%; PV 84% ± 12%; PMF 77% ± 8%) compared to controls (53% ± 11%). Dkk3⁺ megakaryocytes correlated with microvessel density in PV and PMF. We conclude that Dkk3 might be involved in the pathogenesis of MPN.

Keywords

Dickkopf-3 - platelets - megakaryocytes - myeloproliferative neoplasm

^* These senior authors contributed equally to this manuscript.

• References

• 1 Krupnik VE, Sharp JD, Jiang C. et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999; 238: 301-313.
• 2 Ding Z, Qian YB, Zhu LX. et al. Promoter methylation and mRNA expression of DKK-3 and WIF-1 in hepatocellular carcinoma. World J Gastroentero 2009; 15: 2595-2601.
• 3 Sakaguchi M, Kataoka K, Abarzua F. et al. Overexpression of REIC/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7. J Biol Chem 2009; 284: 14236-14244.
• 4 Veeck J, Wild PJ, Fuchs T. et al. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer 2009; 09: 217.
• 5 Barrantes IB, Montero-Pedrazuela A, Guadaño-Ferraz A. et al. Generation and characterization of dickkopf3 mutant mice. Mol Cell Biol 2006; 26: 2317-2326.
• 6 Fong D, Hermann M, Untergasser G. et al. Dkk-3 expression in the tumor endothelium: a novel prognostic marker of pancreatic adenocarcinomas. Cancer Sci 2009; 100: 1414-1420.
• 7 Untergasser G, Steurer M, Zimmermann M. et al. The Dickkopf-homolog 3 is expressed in tumor endothelial cells and supports capillary formation. Int J Cancer 2008; 122: 1539-1547.
• 8 Zitt M, Untergasser G, Amberger A. et al. Dickkopf-3 as a new potential marker for neoangiogenesis in colorectal cancer: expression in cancer tissue and adjacent non-cancerous tissue. Dis Markers 2008; 24: 101-109.
• 9 Zenzmaier C, Untergasser G, Hermann M. et al. Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue. Prostate 2008; 68: 540-547.
• 10 Zenzmaier C, Marksteiner J, Kiefer A. et al. Dkk-3 is elevated in CSF and plasma of Alzheimer‘s disease patients. J Neurochem 2009; 110: 653-661.
• 11 Jaffe EA, Nachman RL, Becker CG. et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756.
• 12 Medinger M, Skoda R, Gratwohl A. et al. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol 2009; 146: 150-157.
• 13 Pfaffl MW. A new mathematical model for relative quantification in real-time RTPCR. Nucleic Acids Res 2001; 29: 45.
• 14 Voorzanger-Rousselot N, Goehrig D, Facon T. et al. Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. Br J Haematol 2009; 145: 264-266.
• 15 Gunsilius E, Petzer A, Stockhammer G. et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000; 58: 169-174.
• 16 Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med 1995; 01: 27-31.
• 17 Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Med 2003; 09: 669-676.
• 18 Italiano Jr JE, Richardson JL, Patel-Hett S. et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-1233.
• 19 Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008; 22: 2020-2028.
• 20 Li Y, Ye X, Tan C. et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 2009; 28: 3442-3455.